Who are Septerna, Inc.'s main suppliers?

Septerna, Inc. (SEPN) key suppliers include: Eli Lilly and Company, Eli Lilly and Company, Novo Nordisk A/S, Novo Nordisk A/S, ORANY and 1 more. View the full supplier network at chainsifter.com/chain/SEPN.

Who are Septerna, Inc.'s major customers?

Septerna, Inc. (SEPN) key customers include: VERTEX, BridgeBio Pharma, Inc., BridgeBio Pharma, Inc., Celldex Therapeutics, Inc., Celldex Therapeutics, Inc. and 18 more. View the full customer network at chainsifter.com/chain/SEPN.

What sector is Septerna, Inc. in?

Septerna, Inc. (SEPN) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

Septerna, Inc. Suppliers, Customers & Supply Chain (SEPN)

6Suppliers

23Customers

2Debt Items

20Related Chains

Source-Backed Evidence Depth

Septerna, Inc. (SEPN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

32Total relationships

4Distinct source URLs

4High confidence

0.737Average confidence

2026-10-28Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Septerna, Inc. Suppliers

Ticker	Name	Confidence	Evidence
LLY	Eli Lilly and Company	72%	ng and sales organization and have no experience as a company in commercializing products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketi…
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from SEPN graph: ng and sales organization and have no…
NVO	Novo Nordisk A/S	72%	ng and sales organization and have no experience as a company in commercializing products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketi…
NVO	Novo Nordisk A/S	72%	Reciprocal relationship from NVO graph: Reciprocal relationship from SEPN graph: ng and sales organization and have no experience as a company in commercializing products, and we may invest significa…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from SEPN graph: rs. If our product candidates are approved, we expect that they will be priced at a significant premium over competi…
ORANY	ORANY	72%	rs. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. Manufacturing and Supply We do not own or operate manufactur…

Septerna, Inc. Customers

Ticker	Name	Confidence	Evidence
VERTEX	VERTEX	92%	For the three months ended March 31, 2025, our revenue was derived solely from research activities performed for Vertex under the Vertex Research Service Agreement.
BBIO	BridgeBio Pharma, Inc.	72%	result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. If any …
BBIO	BridgeBio Pharma, Inc.	72%	Reciprocal relationship from BBIO graph: Reciprocal relationship from SEPN graph: result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requ…
CLDX	Celldex Therapeutics, Inc.	72%	result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. If any …
CLDX	Celldex Therapeutics, Inc.	72%	Reciprocal relationship from CLDX graph: Reciprocal relationship from SEPN graph: result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requ…
GPCR	Structure Therapeutics Inc.	72%	result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. If any …
GPCR	Structure Therapeutics Inc.	72%	Reciprocal relationship from GPCR graph: Reciprocal relationship from SEPN graph: result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requ…
JSPR	Jasper Therapeutics, Inc.	72%	Reciprocal relationship from JSPR graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from JSPR graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from JSPR g…
JSPR	Jasper Therapeutics, Inc.	72%	result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. If any …
LLY	Eli Lilly and Company	72%	Reciprocal relationship from LLY graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from LLY graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from LLY grap…
LLY	Eli Lilly and Company	72%	result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. If any …
MBX	MBX Biosciences, Inc.	72%	result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. If any …
MBX	MBX Biosciences, Inc.	72%	Reciprocal relationship from MBX graph: Reciprocal relationship from SEPN graph: result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requi…
NVO	Novo Nordisk A/S	72%	Reciprocal relationship from NVO graph: Reciprocal relationship from SEPN graph: ng and sales organization and have no experience as a company in commercializing products, and we may invest significa…
NVO	Novo Nordisk A/S	72%	ng and sales organization and have no experience as a company in commercializing products, and we may invest significant resources to develop these capabilities. If we are unable to establish marketi…
ORANY	ORANY	72%	Reciprocal relationship from ORANY graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from ORAN…
ORANY	ORANY	72%	rs. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. Manufacturing and Supply We do not own or operate manufactur…
TERN	Terns Pharmaceuticals, Inc.	72%	Reciprocal relationship from TERN graph: Reciprocal relationship from SEPN graph: result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requ…
TERN	Terns Pharmaceuticals, Inc.	72%	result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. If any …
VKTX	Viking Therapeutics, Inc.	72%	result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates. If any …
VKTX	Viking Therapeutics, Inc.	72%	Reciprocal relationship from VKTX graph: Reciprocal relationship from SEPN graph: result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requ…
BAC	Bank of America Corporation	62%	Reciprocal relationship from BAC graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from BAC graph: Reciprocal relationship from SEPN graph: Reciprocal relationship from BAC grap…
USA-LLC	USA-LLC	62%	rvices industry could lead to losses or defaults by our suppliers, which in turn, could have a material adverse effect on our current and/or planned business operations and our current or projected r…

Septerna, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
SEPN-DEBT	Debt stack $23.1M	90%	Market cache reports total debt of $23.1M.
SEPN-DEBT-12468	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2024-12-31.

Septerna, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Septerna, Inc..

Septerna, Inc. Ownership

Holder	Name	Confidence	Evidence
SEPN-OWNER-RA-CAPITAL-MANAGEMENT-L-P	RA CAPITAL MANAGEMENT, L.P.	90%	13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 125 tracked holders.

Septerna, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
BBIO	BridgeBio Pharma, Inc.	100.00	1	['customer']
BYSI	BeyondSpring Inc.	100.00	2
EDSA	Edesa Biotech, Inc.	100.00	2
LGND	Ligand Pharmaceuticals Incorporated	100.00	2
ORANY	ORANGE	100.00	1	['customer', 'supplier']
ALEC	Alector, Inc.	100.00	2
FHTX	Foghorn Therapeutics Inc.	100.00	2
AKTS	Aktis Oncology, Inc.	100.00	2
CLDX	Celldex Therapeutics, Inc.	100.00	1	['customer']
CTNM	Contineum Therapeutics, Inc.	100.00	2
BBOT	BridgeBio Oncology Therapeutics, Inc.	100.00	2
NVO	Novo Nordisk A/S	100.00	1	['customer', 'supplier']
ALNY	Alnylam Pharmaceuticals, Inc.	100.00	2
SDGR	Schrödinger, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
AXSM	Axsome Therapeutics, Inc.	100.00	2
DSGN	Design Therapeutics, Inc.	100.00	2
DAWN	Day One Biopharmaceuticals Inc	100.00	2
CRSP	CRISPR Therapeutics AG	100.00	2

Septerna, Inc. Supply Chain